Pieris Pharmaceuticals Inc (PIRS) 3.14 $PIRS
Pieris Pharmaceuticals concludes sale of 1.212m common shares in over-allotment option in public offering
M2 - Wed Jul 29, 4:24AM CDT
Biotechnology company Pieris Pharmaceuticals (NasdaqCM
IRS) reported on Tuesday that it has completed the sale of an additional 1,211,827 shares of its common stock as part of the underwriters' over-allotment option under its prior public offering.
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock
Marketwired - Tue Jul 28, 4:00PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced that it closed the sale of an additional 1,211,827 shares of its common stock at the public offering price of $2.75 per share pursuant to the over-allotment option exercised by the underwriters of its recently completed public offering. Including proceeds from the exercise of the over-allotment option, total gross proceeds to Pieris from the offering were $28.3 million before deducting the underwriting discounts, commissions and estimated expenses.
PIRS: 3.14 (-0.06)
5 Stocks Under $10 Set to Soar -- Must-See Charts
at The Street - Thu Jul 16, 10:19AM CDT
Here's a technical look at how to trade five stocks under $10 that look to be setting up to break out.
PIRS: 3.14 (-0.06), MBII: 1.87 (-0.07), ESI: 5.89 (+0.74), SYRX: 1.71 (+0.01), BLFS: 2.20 (+0.06)
OTC Markets Group Announces Second Quarter 2015 Index Performance and Rebalancing
PR Newswire - Thu Jul 16, 6:00AM CDT
OTC Markets Group Inc. ("OTC Markets Group" or "the Company"
(OTCQX: OTCM) today announced the second quarter 2015 performance and quarterly rebalancing of the OTCQX® indexes, the OTCQB® Venture Index, the OTCM QX ADR Index ("OTCQX30" and the OTCM ADR Index.
CETX: 2.74 (-0.06), PIRS: 3.14 (-0.06), RELY: 11.36 (+0.40), CRBP: 2.05 (+0.12), ONCS: 6.27 (unch), CYNA: 16.31 (-0.20), BPMX: 2.18 (+0.06), CXRX: 81.00 (+2.04)
Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Marketwired - Wed Jul 08, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo", and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates.
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals Closes Public Offering of Common Stock
Marketwired - Mon Jul 06, 2:59PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the closing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share.
PIRS: 3.14 (-0.06)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT
FIT: 44.42 (-1.05), PIRS: 3.14 (-0.06), KITE: 70.15 (-1.76), SRPT: 31.72 (-0.31), WSH: 46.69 (+0.50), CALA: 7.53 (-0.59), CLLS: 35.85 (-0.53), LBIO: 8.48 (-0.33), JUNO: 48.01 (-0.61), PNR: 60.51 (+1.06), APOL: 13.21 (-0.17), DSKX: 3.42 (+0.18)
Pieris Pharmaceuticals Prices Public Offering of Common Stock
Marketwired - Tue Jun 30, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the pricing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share. All shares of common stock are being offered by the company. In addition, Pieris has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the same price to cover any over-allotments.
PIRS: 3.14 (-0.06)
Week Ahead: Get Ready For A Dose Of High-Growth Healthcare With 7 IPOs
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 29, 1:40AM CDT
As many as 7 companies could go public in the US during the shortened holiday week. The week's three high-growth health care IPOs that are on the IPO calendar should receive the most interest, especially after device maker Glaukos (Pending: GKOS )...
CNXC: 14.55 (-0.36), PIRS: 3.14 (-0.06), TDOC: 31.37 (+0.54), CFMS: 22.50 (+0.11), NTRA: 18.45 (+0.41)
Week Ahead: As Many As 16 IPOs Could Price During The Week Of June 22
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 22, 10:31AM CDT
16 companies are on the calendar to go public this week and raise $2.5 billion. It should be the year's most active week in the IPO market; the second busiest week saw 10 IPOs in January. Investors have plenty of options this week, so expect IPO...
TRU: 24.99 (+0.39), PIRS: 3.14 (-0.06), CATB: 12.91 (-0.18), WNFM: (), GKOS: 30.72 (-0.05), APPF: 14.57 (-0.13), LNTH: 6.75 (+0.04), YECO: 4.11 (+0.15), MCRN: 19.14 (-0.23), ALRM: 17.50 (+0.42), MCRB: 36.26 (-0.16)
Pieris Pharmaceuticals on deck for IPO and uplisting
Seeking Alpha - at Seeking Alpha - Fri Jun 19, 3:39PM CDT
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia
Marketwired - Wed Jun 10, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company's PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.
PIRS: 3.14 (-0.06)
Recent News Highlights Pieris's Efforts In Immuno-Oncology
Jason Napodano, CFA - at Seeking Alpha - Fri May 22, 6:36AM CDT
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference
Marketwired - Tue May 19, 6:31AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO, Stephen Yoder, will present preclinical data on a new immuno-oncology program -- an Anticalin-based CD137-HER2 bispecific -- at the UBS Global Healthcare Conference at 4:30 pm EDT.
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals concludes sale of 1.212m common shares in over-allotment option in public offering
M2 - Wed Jul 29, 4:24AM CDT
Biotechnology company Pieris Pharmaceuticals (NasdaqCM
IRS) reported on Tuesday that it has completed the sale of an additional 1,211,827 shares of its common stock as part of the underwriters' over-allotment option under its prior public offering. PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock
Marketwired - Tue Jul 28, 4:00PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced that it closed the sale of an additional 1,211,827 shares of its common stock at the public offering price of $2.75 per share pursuant to the over-allotment option exercised by the underwriters of its recently completed public offering. Including proceeds from the exercise of the over-allotment option, total gross proceeds to Pieris from the offering were $28.3 million before deducting the underwriting discounts, commissions and estimated expenses.
PIRS: 3.14 (-0.06)
5 Stocks Under $10 Set to Soar -- Must-See Charts
at The Street - Thu Jul 16, 10:19AM CDT
Here's a technical look at how to trade five stocks under $10 that look to be setting up to break out.
PIRS: 3.14 (-0.06), MBII: 1.87 (-0.07), ESI: 5.89 (+0.74), SYRX: 1.71 (+0.01), BLFS: 2.20 (+0.06)
OTC Markets Group Announces Second Quarter 2015 Index Performance and Rebalancing
PR Newswire - Thu Jul 16, 6:00AM CDT
OTC Markets Group Inc. ("OTC Markets Group" or "the Company"
(OTCQX: OTCM) today announced the second quarter 2015 performance and quarterly rebalancing of the OTCQX® indexes, the OTCQB® Venture Index, the OTCM QX ADR Index ("OTCQX30" and the OTCM ADR Index. CETX: 2.74 (-0.06), PIRS: 3.14 (-0.06), RELY: 11.36 (+0.40), CRBP: 2.05 (+0.12), ONCS: 6.27 (unch), CYNA: 16.31 (-0.20), BPMX: 2.18 (+0.06), CXRX: 81.00 (+2.04)
Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Marketwired - Wed Jul 08, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo"
, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates. PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals Closes Public Offering of Common Stock
Marketwired - Mon Jul 06, 2:59PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the closing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share.
PIRS: 3.14 (-0.06)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT
FIT: 44.42 (-1.05), PIRS: 3.14 (-0.06), KITE: 70.15 (-1.76), SRPT: 31.72 (-0.31), WSH: 46.69 (+0.50), CALA: 7.53 (-0.59), CLLS: 35.85 (-0.53), LBIO: 8.48 (-0.33), JUNO: 48.01 (-0.61), PNR: 60.51 (+1.06), APOL: 13.21 (-0.17), DSKX: 3.42 (+0.18)
Pieris Pharmaceuticals Prices Public Offering of Common Stock
Marketwired - Tue Jun 30, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the pricing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share. All shares of common stock are being offered by the company. In addition, Pieris has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the same price to cover any over-allotments.
PIRS: 3.14 (-0.06)
Week Ahead: Get Ready For A Dose Of High-Growth Healthcare With 7 IPOs
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 29, 1:40AM CDT
As many as 7 companies could go public in the US during the shortened holiday week. The week's three high-growth health care IPOs that are on the IPO calendar should receive the most interest, especially after device maker Glaukos (Pending: GKOS )...
CNXC: 14.55 (-0.36), PIRS: 3.14 (-0.06), TDOC: 31.37 (+0.54), CFMS: 22.50 (+0.11), NTRA: 18.45 (+0.41)
Week Ahead: As Many As 16 IPOs Could Price During The Week Of June 22
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 22, 10:31AM CDT
16 companies are on the calendar to go public this week and raise $2.5 billion. It should be the year's most active week in the IPO market; the second busiest week saw 10 IPOs in January. Investors have plenty of options this week, so expect IPO...
TRU: 24.99 (+0.39), PIRS: 3.14 (-0.06), CATB: 12.91 (-0.18), WNFM: (), GKOS: 30.72 (-0.05), APPF: 14.57 (-0.13), LNTH: 6.75 (+0.04), YECO: 4.11 (+0.15), MCRN: 19.14 (-0.23), ALRM: 17.50 (+0.42), MCRB: 36.26 (-0.16)
Pieris Pharmaceuticals on deck for IPO and uplisting
Seeking Alpha - at Seeking Alpha - Fri Jun 19, 3:39PM CDT
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia
Marketwired - Wed Jun 10, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company's PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.
PIRS: 3.14 (-0.06)
Recent News Highlights Pieris's Efforts In Immuno-Oncology
Jason Napodano, CFA - at Seeking Alpha - Fri May 22, 6:36AM CDT
PIRS: 3.14 (-0.06)
Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference
Marketwired - Tue May 19, 6:31AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO, Stephen Yoder, will present preclinical data on a new immuno-oncology program -- an Anticalin-based CD137-HER2 bispecific -- at the UBS Global Healthcare Conference at 4:30 pm EDT.
PIRS: 3.14 (-0.06)
